10-Q: Cassava Sciences Reports Third Quarter 2024 Financial Results and Provides Clinical Program Updates

Cassava Sciences' Phase 3 Alzheimer's drug Simufilam shows promise in trials, with top-line results for the 52-week study expected by the end of 2024, despite ongoing legal challenges and leadership changes.

Summary

• Cassava Sciences is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease.
• Their lead drug candidate, Simufilam, is in Phase 3 clinical trials, with the 52-week study results expected by the end of 2024 and the 76-week study results by mid-2025.
• Simufilam aims to stabilize a critical protein in the brain, potentially improving cognition and reducing neuroinflammation.
• The company reported a net loss of $27.9 million for Q3 2024, compared to a net loss of $25.7 million in Q3 2023.
• Research and development expenses decreased due to the completion of Phase 3 enrollment, while general and administrative expenses increased significantly due to legal costs and a $40 million SEC settlement.
• The company has faced legal challenges, including securities class action lawsuits and government investigations, resulting in substantial legal expenses and a settlement with the SEC.
• Leadership changes occurred, with Richard J. Barry appointed as President and CEO, succeeding Remi Barbier.
• Despite these challenges, Cassava Sciences remains focused on its Phase 3 clinical program and believes it has sufficient cash to fund operations for at least the next 12 months.

Sentiment

Score: 4

Explanation: The sentiment is relatively low due to the significant legal challenges, the SEC settlement, the indictment of a former collaborator, questions surrounding the Phase 2b study, and increased operating losses. However, the ongoing Phase 3 trials and the potential of Simufilam provide some balance to the negative aspects.

Positives

• Simufilam has shown promising results in clinical trials, potentially offering a new treatment approach for Alzheimer's disease.
• The company has a strong intellectual property portfolio, with exclusive worldwide rights to its drug and diagnostic assets.
• The completion of enrollment in the Phase 3 trials is a significant milestone.
• The DSMB's recommendation to continue the Phase 3 studies without modification is a positive sign.
• Interim MRI safety data suggests a favorable safety profile for Simufilam.
• The company believes it has sufficient cash to fund operations for at least the next 12 months.

Negatives

• The company reported a net loss of $27.9 million for Q3 2024.
• General and administrative expenses increased significantly due to legal costs and the SEC settlement.
• The company faces ongoing legal challenges, including securities class action lawsuits and government investigations.
• The company's former scientific collaborator, Dr. Hoau-Yan Wang, was indicted by the DOJ for alleged research misconduct.
• The validity of aspects of the Company's Phase 2b Study has been called into question.
• The company experienced leadership changes, including the resignation of the former CEO and a former Senior Vice President.

Risks

• The outcome of the Phase 3 clinical trials is uncertain, and Simufilam may not demonstrate efficacy or safety.
• The company may face difficulty obtaining regulatory approval for Simufilam.
• The company may be unable to commercialize Simufilam successfully.
• The company may face competition from other Alzheimer's disease treatments.
• The company may need to raise additional capital in the future, which may not be available on favorable terms.
• Ongoing legal proceedings and government investigations could result in significant financial penalties and reputational damage.
• The company's stock price may be volatile and subject to significant fluctuations.
• The indictment of Dr. Wang and questions surrounding the Phase 2b study may negatively impact the company's reputation and future prospects.

Future Outlook

The company anticipates top-line data readout for its 52-week Phase 3 study (RETHINK-ALZ) by the end of 2024 and for its 76-week study (REFOCUS-ALZ) approximately mid-year 2025. They expect research and development expenses to decrease in future periods due to the completion of Phase 3 enrollment but to be partially offset by increased enrollment in the open-label study and higher stock-based compensation expense. General and administrative expenses are expected to remain high due to ongoing legal proceedings.

Management Comments

• The database for each Phase 3 study will be sent directly from the CRO to the biostatisticians at Pentara.
• Only then will the statisticians receive unblinding codes from the CRO.
• Pentara will notify us when their top-line statistical analyses have been completed.
• Cassava will have no access to the unblinded data until after Pentara has performed its statistical analyses.
• Similarly, plasma samples are being provided directly to an independent, accredited commercial laboratory, which will perform analyses of these samples under blinded conditions.

Industry Context

Cassava Sciences is operating in the challenging field of Alzheimer's disease treatment development, where many companies have faced setbacks. The focus on stabilizing the FLNA protein, rather than clearing amyloid, differentiates Cassava's approach from many competitors. The ongoing Phase 3 trials and the company's unique scientific approach position it as a notable player in the industry, despite the legal and regulatory challenges it faces.

Comparison to Industry Standards

• In comparison to Biogen's Aduhelm, which received accelerated approval based on amyloid reduction but faced controversy regarding its clinical benefit, Simufilam's focus on stabilizing FLNA protein offers a different mechanism of action.
• Eli Lilly's donanemab, another amyloid-targeting antibody, showed a slowing of cognitive decline in trials, but also carries the risk of ARIA, a side effect that Simufilam has not shown in interim safety data.
• Compared to Eisai and Biogen's lecanemab, which also targets amyloid and has shown some clinical benefit, Simufilam's oral administration could offer a more convenient treatment option if proven effective.
• Roche's gantenerumab, another anti-amyloid antibody, failed to meet its primary endpoint in recent Phase 3 trials, highlighting the challenges in targeting amyloid. Simufilam's different approach may offer an alternative pathway for treatment.

Management Changes

Legal Proceedings

• The company reached a settlement with the SEC, agreeing to pay a $40 million civil monetary penalty to resolve the SEC investigation of the Company's disclosures regarding its Phase 2b clinical trial of Simufilam.
• Four putative class action lawsuits were filed alleging violations of the federal securities laws by the company and certain named officers.
• A related shareholder derivative action was filed on November 4, 2021, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Companys Board.
• On November 9, 2023, another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.
• On February 2, 2024, a putative class action lawsuit was filed, purportedly on behalf of the Company, alleging violations of the federal securities law by the Company and certain named officers.
• Beginning on March 18, 2024, two related shareholder derivative actions were filed, purportedly on behalf of the Company, in the U.S. District Court for the Northern District of Illinois, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Companys Board.
• On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Companys Board.
• On August 6, 2024, a lawsuit was filed in the District Court for the Southern District of New York which, as amended, asserts claims, including a claim under the New York Anti-SLAPP Law, against the Company and against two former officers to whom the Company has certain indemnification obligations.

Related Party Transactions

• Included in accrued compensation and benefits at September 30, 2024 is approximately $1.7 million of accrued severance costs for two former senior officers of the Company, including our former Chief Executive Officer.
• On July 16, 2024, the Company entered into a one-year consulting agreement with the Companys former Senior Vice President, Neuroscience. Pursuant to the terms of the consulting agreement, the consultant is providing services for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Companys products. The Company will pay $500 per hour for such consulting services.
• The Company incurred fees totaling $29,000 under the consulting agreement during the three months ended September 30, 2024.

Stakeholder Impact

• Shareholders may be impacted by the outcome of the Phase 3 trials, the resolution of legal proceedings, and the company's financial performance.
• Employees may be impacted by leadership changes, the company's financial stability, and the success or failure of Simufilam.
• Customers (patients with Alzheimer's disease) may be impacted by the availability and effectiveness of Simufilam as a treatment option.
• Suppliers and creditors may be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• Completion of the 52-week Phase 3 RETHINK-ALZ study and release of top-line results by the end of 2024.
• Completion of the 76-week Phase 3 REFOCUS-ALZ study and release of top-line results approximately mid-year 2025.
• Continued monitoring of patients in the open-label extension study.
• Potential expansion of the open-label extension studies by up to an additional 36 months.
• Resolution of ongoing legal proceedings and government investigations.
• Submission of a statistical analysis plan (SAP) to the FDA for the Phase 3 trials.

Key Dates

Keywords

Alzheimer's disease, Simufilam, neurodegenerative diseases, clinical trials, Phase 3, biotechnology, drug development, SavaDx, SEC settlement, FDA